REMAXOL: MECHANISMS OF ACTION AND APPLICATION IN REAL CLINICAL PRACTICE. Part II
https://doi.org/10.20514/2226-6704-2016-6-3-8-18
Abstract
Окончание. Начало читайте в Томе 6, номере 2(28)-2016 г.
About the Authors
L. Yu. Ilchenko
Federal State budget institution of higher education «Pirogov Russian National Research Medical University»
Russian Federation
Russian Federation
Department of Medical Faculty Hospital Therapy № 2,
Moscow
S. V. Okovityi
Federal State budget institution of higher education «Saint-Petersburg State Chemical-Pharmaceutical Academy»
Russian Federation
Russian Federation
Department of Pharmacology and Clinical Pharmacology,
Saint-Petersburg
References
1. Gressner A.M., Schuppan D. Cellular and molecular pathobiology, pharmacological intervention, and biochemical assessment of liver fibrosis. Oxford textbook of clinical hepatology. Oxford, UK: Oxford University Press, 1999: 607-629.
2. Babak O.Ya. Drug-induced hepatopathies: theory and practice. Traven`. 2008; 4: 83-88.
3. Nath B., Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatol. 2012; 55(2): 622-633.
4. Balasaniants G.S. Hepatotoxic reactions and hepatoprotective therapy in phthisiology. Tubercul. Lung Dis. 2015; 8: 48-52.
5. Navarro V.J., Senior J.R. Drug-related hepatotoxicity. NEJM. 2006; 354 (7): 731-739.
6. Baranova I.P., Zykova O.A., Krasnova L.I. et al. Efficiency of remaxol in preventing unwanted side effects of the antiviral therapy in patients with chronic hepatitis C. Exper. Clin. Phrmacol. 2013; 11: 44-46.
7. Pessayre D. Central role of mitochondria in drug-induced liver injury. Drug Met. Rev. 2012; 44(1): 34-87.
8. Bezborodkina N.N., Okovity S.V., Kudryavtseva M.V. et al. Morphometry of hepatocyte mitochondrial apparatus in normal and cirrhotic rat liver. Tsitologia. 2008; 50: 228-236.
9. Sheikh M.Y, Choi J., Qadri I. et al. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatol. 2008; 47(6): 2127-2133.
10. Bezborodova O.A., Nemtsova E.R., Venediktova Iu.B. et al. Experimental study of remaxol as a drug for supportive therapy in traditional and high-dose treatment of tumors. Eksper. Klin. Farmakol. 2013; 5: 18-22.
11. Sikuler E., Kravetz D., Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am. J. Physiol. 1985, 248: 618-625.
12. Zarivchatskii M.F., Kamenskikh E.D., Mugatarov I.N. The efficacy of emaxol in patients with liver cirrhosis. Surgery. 2013; 3: 79-82.
13. Tarantino G., Minno M.N.D., Capone D. Drug-induced liver injury: is it somehowforeseeable? World J. Gastroenterol. 2009; 15 (23): 2817-2833.
14. Karelov A.E., Pyshnaya I.V., Mitrokhina M.V. et al. The efficacy of hepatotropic agent remaxol in oncological patients with postoperative liver dysfunction. Eksper. Klin. Farmakol. 2013; 7: 19-23.
15. Vidali M., Hidestrand M., Eliasson E. et al. Use of molecular simulation for mapping conformational CYP2E1 epitopes. J. Biol. Chem. 2004; 279 (49): 50949-50955.
16. Konopatskova O.M., Averyanova S.V. Accompanying therapy polyche-motherapy during breast cancer. Experience of remaxsol. Oncol. J. Gertsen. 2015; 4(6): 35-37.
17. Wu J.A., Danielsson A. Detection of hepatic fibrogenesis: a review of available techniques. Scand. J. Gastroenterol. 1995; 30: 817-825.
18. Konopatskova O.M., Averyanova S.V. Adjunct therapy during combination chemotherapy for colorectal cancer. Oncol. J. Gertsen. 2016; 5(1): 42-46.
19. Yang S., Tan T.M., Wee A., Leow C.K. Mitochondrial respiratory function and antioxidant capacity in normal and cirrhotic livers following partial hepatectomy. Cell. Mol. Life. Sci. 2004; 61: 220-229.
20. Kudryavtseva M.V., Bezborodkina N.N., Okovity S.V., Kudryavtsev B.N. Carbohydrate metabolism in chronic liver disease. SPb.: Sintez-Buk, 2008, 176.
21. Luk`yanova L.D. Molecular mechanisms of hypoxia and modern approaches of pharmacological correction of hypoxic violations. Abstracts of all-Russian scientific Conference. SPb., 2004; 36-39.
22. Matyakin G.G., Ivanov V.M., Ivanova O.V., Sheikin M.M. Toxicity modifying action of remaxol by treatment of advanced oral cancer. 2013; 6: 12-15.
23. Mordyk A.V., Ivanova O.G., Nagibina L.A. et al. Drug-induced liver lesions and their management in the manifestations of tuberculosis. Tubercul. Lung Dis. 2015; 8: 47-52.
24. Okovity S.V., Sukhanov D.S., Zaplutanov V.A., Smagina А.N. Antihypoxants in current clinical practice. Clin. Med. 2012; 90 (9): 69-74.
25. Okovityi S.V., Padko S.V. Mitochondrial dysfunctions' role in pathogenesis of different liver disorders. Doctor.Ru. Gastroenterology. 2015; 12 (113): 30-33.
26. Okovityi S.V., Radko S.V., Shustov E.B. Succinate receptors (SUCNR1) as a promising target for pharmacotherapy. J. Chem. pharmac. 2015; 9: 24-28.
27. Orlov Yu.P., Lukach V.N., Govorov et al. Place remaxol as a hepatoprotector in intensive therapy of pervasive peritonitis. Rus. J. Anaesthesiol. 2015; 6: 24-28.
28. Pavelkina V.F., Ampleeva N.P. Comparative effectiveness hepatotropic activity remaxol and Essentiale N in chronic viral hepatitis. Eksper. Klin. Farmakol. 2014; 12: 17-21.
29. Sologub T.V., Goryacheva L.G., Sukhanov D.S. et al. Hepatoprotective activity of remaxol in chronic liver damage (materials a multicenter, randomized, placebo-controlled study). Clin. Med. 2010; 1: 62-66.
30. Sukhanov D.S., Pomantsov M.G. Hepatoprotector effects at liver lesion in respiratory organs tuberculosis patients. Advances in current natural sciences. 2008; 10: 40-50.
31. Sukhanov D.S., Ivanov A.K., Romantsov M.G., Kovalenko A.L. Treatment of hepatotoxic complications of antituberculosis therapy of succinate - containing drugs. RMJ. 2009; 6: 22-25.
32. Sukhanov D.S., Vinogradova T.I., Zabolotnykh N.V. et al. The effect of succinate - containing drugs on regeneration processes in the experiment. Surgery. 2011; 1: 56-60.
33. Sukhanov D.S., Vinogradova T.I., Zabolotnykh N.V. et al. Comparative study of hepatoprotective action of remaxol, reamberin and ademethionine in liver injury induced by antituberculosis drugs (experimental study). Antibiot. Chemother. 2011; 1-2: 13-17.
34. Sukhanov D.S., Kovalenko A.L., Romantsov M.G., Experimental study of cytoprotector effect of succinate-containing drug on functional activity of liver. Eksper. Klin. Farmakol. 2010; 8: 35-38.
35. Sukhanov D.S., Okovityi S.V., Yablonskyi P.K. et al. Hepatotropic therapy in treatment of liver injury. Antibiot. Chemother. 2012; 5-6: 41-52.
36. Sukhanov D.S. Antioxidant properties of remaxol, reamberin, and ademetionine in patients with drug-induced liver injury on the background of antituberculous therapy. Eksper. Klin. Farmakol. 2013; 4: 45-48.
37. Sukhanov D.S., Pavlova M.V., Vinogradova T.I. Clinical efficacy of succinic acid based infusion solutions in the therapy of liver damages caused by antituberculosis drugs. Tubercul. Lung Dis. 2013; 8: 50-56.
38. Sukhanov D.S., Pavlova M.V., Yablonskyi P.K., Vinogradova T.I. Comparative efficacy of clinical use of reamberin, remaxol and ademethionine in patients with tuberculosis of the respiratory organs and liver-drug injury. Antibiot. Chemother. 2013; 58(1-2): 13-18.
39. Stel`makh V.V., Kozlov V.K. Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy. Ter. Arkh. 2013; 4: 71-76.
40. Stel`makh V.V., Kozlov V.K., Baranov V.L. et al. Energotropic pathogenetically oriented therapy succinyladenosine drugs by nonalcoholic fatty liver disease. Prospects of clinical application. Med. Alphabet. Gastroenterol.
41. Stelmakh V.V., Kozlov V.K., Ivanova V.F., Samusenko I.A. Efficacy of the infusion hepatotropic drug remaxol in the pathogenetic therapy for cirrhotic stage chronic viral hepatitides. Ter. Arkh. 2015; 8: 67-72.
42. Stupin V.A., Basarbolieva Zh.V., Agapov M.A. et al. Treatment of hepatic insufficiency in benign mechanical jaundice. Clin. Med. 2013.; 11: 53-56.
43. Tumanyan S.V., Yartseva D.V. Effect of hepatic functional activity of the liver and endogenous intoxication in patients with ovarian cancer. Surgery. 2014; 11: 45-47.
44. Khoronenko V.E., Donskova Yu.S., BaskakovD.S. et al. Prophylaxis of hepatic insufficiency after major hepatic resections. Rus. J. Anaesthesiol. 2014; 4: 33-38.
45. Cherenkov V.G., Petrov A.B., Basilieva T.M., Storozhenkov M.M. Possibilities of remaxsol in prevention of toxic hepatitis during chemotherapy for cancer patients. Problems in oncol. 2013; 3: 369-374.
46. Shevyreva E.V., Ivanov A.K., Suchanov D.S., Murzina A.A. Remaxol hepatoprotective therapy of patients with tuberculosis and HIV infection in day unit of tuberculosis dispensary. Antibiot. Chemother. 2012; 7-8: 33-37.
47. Yakovenko E.P., Yakovenko A.V., Ivanov A.N., Agafonova N.A. Pathogenetic approaches to therapy drugs liver damages. Consilium medicum (Gastroenterol). 2009; 1: 27-31.
48. Yakovlev A.Yu., Niyazmatov A.A., Zarechnova N.V., Zaitsev R.R. et al. Effect of antihypoxant infusion on microbial endotoxin circulation in obstructive jaundice patients. Eksper. Klin. Farmakol. 2013; 2: 28-31.
49. Yakovlev A.Yu., Chichkanova A.S., Ulitin D.S. et al. Correction of hepatic dysfunction as pre-treatment before systemic chemotherapy in patients with bile duct neoplasms. Problems in oncol. 2012; 4: 555-558.
50. Au J.S., Navarro V.J., Rossi S. Drug-induced liver injury-its pathophysiology and evolving diagnostic tools. Aliment. Pharmacol. Ther. 2011; 34 (1): 11-20.
51. Blad C.C., Tang C., Offermanns S. G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat. Rev. Drug Discovery. 2012; 11 (8): 603-619.
52. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Inv. 2004; 114(2): 147-152.
53. Begriche K., Massart J., Robin M.A. et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatol. 2013; 58(4): 1497-1507.
54. Day C., James O. Steatohepatitis: a tale of two «hits»? Gastroenterol. 1998; 14: 842–845.
55. Deen P.M.T., Robben J.H. Succinate Receptors in the kidney. J. Am. Soc. Nephrol. 2011; 22(8): 1416-1422.
56. Grattagliano I., de Bari O., Bernardo T.C. et al. Role of mitochondria in nonalcoholic fatty liver disease-from origin to propagation. Clin. Biochem. 2012; 45: 610-618.
57. Gressner A.M., Schuppan D. Cellular and molecular pathobiology, pharmacological intervention, and biochemical assessment of liver fibrosis. Oxford textbook of clinical hepatology. Oxford, UK: Oxford University Press, 1999: 607-629.
58. Nath B., Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatol. 2012; 55(2): 622-633.
59. Navarro V.J., Senior J.R. Drug-related hepatotoxicity. NEJM. 2006; 354 (7): 731-739.
60. Pessayre D. Central role of mitochondria in drug-induced liver injury. Drug Met. Rev. 2012; 44(1): 34-87.
61. Sheikh M.Y, Choi J., Qadri I. et al. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatol. 2008; 47(6): 2127-2133.
62. Sikuler E., Kravetz D., Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am. J. Physiol. 1985, 248: 618-625.
63. Tarantino G., Minno M.N.D., Capone D. Drug-induced liver injury: is it somehowforeseeable? World J. Gastroenterol. 2009; 15 (23): 2817-2833.
64. Vidali M., Hidestrand M., Eliasson E. et al. Use of molecular simulation for mapping conformational CYP2E1 epitopes. J. Biol. Chem. 2004; 279 (49): 50949-50955.
65. Wu J.A., Danielsson A. Detection of hepatic fibrogenesis: a review of available techniques. Scand. J. Gastroenterol. 1995; 30: 817-825.
66. Yang S., Tan T.M., Wee A., Leow C.K. Mitochondrial respiratory function and antioxidant capacity in normal and cirrhotic livers following partial hepatectomy. Cell. Mol. Life. Sci. 2004; 61: 220-229.
Review
For citations:
Ilchenko L.Yu., Okovityi S.V. REMAXOL: MECHANISMS OF ACTION AND APPLICATION IN REAL CLINICAL PRACTICE. Part II. The Russian Archives of Internal Medicine. 2016;6(3):8-18. (In Russ.) https://doi.org/10.20514/2226-6704-2016-6-3-8-18
Views:
1914
Email this article 